908 related articles for article (PubMed ID: 16519038)
1. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
[TBL] [Abstract][Full Text] [Related]
2. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
[TBL] [Abstract][Full Text] [Related]
3. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
4. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.
Davidson JA; Liebl A; Christiansen JS; Fulcher G; Ligthelm RJ; Brown P; Gylvin T; Kawamori R
Clin Ther; 2009 Aug; 31(8):1641-51. PubMed ID: 19808125
[TBL] [Abstract][Full Text] [Related]
5. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
Hermansen K; Colombo M; Storgaard H; ØStergaard A; Kølendorf K; Madsbad S
Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
[TBL] [Abstract][Full Text] [Related]
6. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus.
McSorley PT; Bell PM; Jacobsen LV; Kristensen A; Lindholm A
Clin Ther; 2002 Apr; 24(4):530-9. PubMed ID: 12017398
[TBL] [Abstract][Full Text] [Related]
7. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
[TBL] [Abstract][Full Text] [Related]
8. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
[TBL] [Abstract][Full Text] [Related]
9. Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review.
Gough SC; Tibaldi J
Clin Drug Investig; 2007; 27(5):299-324. PubMed ID: 17451279
[TBL] [Abstract][Full Text] [Related]
10. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
Rys P; Wojciechowski P; Siejka S; Małecki P; Hak L; Malecki MT
Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
[TBL] [Abstract][Full Text] [Related]
11. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
[TBL] [Abstract][Full Text] [Related]
12. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
[TBL] [Abstract][Full Text] [Related]
13. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
Hussein Z; Lim-Abrahan MA; Jain AB; Goh SY; Soewondo P
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study.
Morgan CL; Evans M; Toft AD; Jenkins-Jones S; Poole CD; Currie CJ
Clin Ther; 2011 Jan; 33(1):27-35. PubMed ID: 21397771
[TBL] [Abstract][Full Text] [Related]
15. Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.
Farshchi A; Aghili R; Oskuee M; Rashed M; Noshad S; Kebriaeezadeh A; Kia M; Esteghamati A
BMC Endocr Disord; 2016 Jun; 16(1):35. PubMed ID: 27278922
[TBL] [Abstract][Full Text] [Related]
16. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients.
Boehm BO; Home PD; Behrend C; Kamp NM; Lindholm A
Diabet Med; 2002 May; 19(5):393-9. PubMed ID: 12027927
[TBL] [Abstract][Full Text] [Related]
17. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
19. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
[TBL] [Abstract][Full Text] [Related]
20. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials.
Fonseca V; Davidson J; Home P; Snyder J; Jellinger P; Dyhr Toft A; Barnett A
Curr Med Res Opin; 2010 Jul; 26(7):1621-8. PubMed ID: 20429817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]